戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1     These findings suggest that the reported insulin-like actions of GLP-1 receptor agonists that occ
2 synaptic function, could be preserved by the insulin-like effect of lipoic acid.
3  circulating monoamine oxidase activity, has insulin-like effects, and can initiate oxidative stress.
4  receptor, muscarinic 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1).
5            One lying upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (chromoso
6  in adult males via interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).
7 rogenitor cells and upregulate expression of insulin-like genes in starved L1 larvae.
8                  We further demonstrate that insulin like growth factor signaling may mediate the pro
9           However, the possible roles of the insulin like growth factor-1 receptor (IGF-1R) on neuron
10                 Growth-related glycoproteins insulin-like growth factor (IGF) 1, IGF binding protein-
11                                          The insulin-like growth factor (IGF) axis may be implicated
12 however, data on mutations in IGF2, encoding insulin-like growth factor (IGF) II, are lacking.
13 stoma, is driven by Sonic hedgehog (Shh) and insulin-like growth factor (IGF) in the developing cereb
14                            Signaling via the insulin-like growth factor (IGF) pathway is aberrantly a
15                                          The insulin-like growth factor (IGF) receptor (IGF-IR) is ne
16                              Lowered insulin/insulin-like growth factor (IGF) signaling (IIS) can ext
17  the sirtuin family of proteins, the insulin/insulin-like growth factor (IGF) signaling (IIS) pathway
18 D) progression is significantly delayed when insulin-like growth factor (IGF) signaling is blocked in
19                                  The insulin/insulin-like growth factor (IGF) signaling pathway plays
20                                              Insulin-like growth factor (IGF) signaling plays an impo
21 d plasma protein-A (PAPP-A), which modulates insulin-like growth factor (IGF) signaling through prote
22  study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/1
23                                          The insulin-like growth factor (IGF) system is a well-studie
24 .0001), insulin (r(2) = 0.40, P < 0.005) and insulin-like growth factor (IGF)-1 (r(2) = 0.80, P < 0.0
25                                  The insulin/insulin-like growth factor (IGF)-1 signaling pathway (IS
26 AT3 phosphorylation by interleukin-6 (IL-6), insulin-like growth factor (IGF)-1, IGF-2, and leukemia
27 notype were accompanied by altered placental insulin-like growth factor (IGF)-2 expression and insuli
28                   Aberrant regulation of the insulin-like growth factor (IGF)/insulin (IIS)-PI3K-AKT-
29 , including Wnt/beta-catenin, Prolactin, and insulin-like growth factor (IGF)1 signaling.
30  A focus on reversible mechanisms identified Insulin-like growth factor (IGF1) deficiency with inadeq
31        To determine the roles of insulin and insulin-like growth factor 1 (IGF-1) action in adipose t
32 ric dysfunction (EED) and disturbance of the insulin-like growth factor 1 (IGF-1) axis.
33                                        Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid
34                                              Insulin-like Growth Factor 1 (IGF-1) is associated with
35                                              Insulin-like growth factor 1 (IGF-1) is known to have di
36 mones and neuropeptides, such as insulin and insulin-like growth factor 1 (IGF-1) likely modulate gly
37 spective case-control studies suggested that insulin-like growth factor 1 (IGF-1) or insulin-like gro
38 t or energy levels-most notably, the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway,
39 nction through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway.
40 liferation by modulating a decrease in serum insulin-like growth factor 1 (IGF-1) that allows GH rele
41 f the pro-osteoclastogenic factors RANKL and insulin-like growth factor 1 (IGF-1) to induce osteoclas
42            Finally, we studied the impact of insulin-like growth factor 1 (IGF-1) treatment on CDKL5
43 anismal level as shown by down-regulation of insulin-like growth factor 1 (IGF-1), a hallmark of prem
44                              Serum levels of insulin-like growth factor 1 (IGF-1), a hormone with kno
45 pe 2 diabetes mellitus (T2DM) via binding of insulin-like growth factor 1 (IGF-1), an insulin-like ho
46 ng serum concentrations of glucose, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growt
47            We previously established that an insulin-like growth factor 1 (IGF-1)-inducible mitochond
48 n-associated cytokines, macrophages released insulin-like growth factor 1 (IGF-1).
49 ress osteopontin (OPN) and receptors for the insulin-like growth factor 1 (IGF-1).
50 y, and low circulating levels of insulin and insulin-like growth factor 1 (IGF-1).
51 gate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1).
52 +DE patient serum revealed altered levels of insulin-like growth factor 1 (IGF-I) and its binding pro
53 o-expression of two soluble proteins, namely insulin-like growth factor 1 (IGF1) and osteopontin (OPN
54                                              Insulin-like growth factor 1 (IGF1) and phosphoinositol
55 ingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of
56                                              Insulin-like growth factor 1 (IGF1) has potent trophic e
57  novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma.
58                                              Insulin-like growth factor 1 (IGF1) is secreted in an au
59  receptor tyrosine kinases by neuregulin and insulin-like growth factor 1 (IGF1) leads to the phospho
60 ic species with high binding affinity to the insulin-like growth factor 1 (IGF1) receptor.
61 ffects of (56)Fe radiation on adipokines and insulin-like growth factor 1 (IGF1) signaling axis in mo
62 toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and preve
63  Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical proto
64 reased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in grow
65 or muscle growth, including the induction of insulin-like growth factor 1 (IGF1), as well as concomit
66 ted sites cluster on the binding surfaces of insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1
67 n, or co-overexpression of osteopontin (OPN)/insulin-like growth factor 1 (IGF1)/ciliary neurotrophic
68 cer pinpoint to a potential new function for insulin-like growth factor 1 (Igf1r) in the basal epithe
69 ands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone l
70                           Supplementation of insulin-like growth factor 1 partially reverted the DR-i
71 the insulin receptor (F-IRKO) or both IR and insulin-like growth factor 1 receptor (F-IR/IGFRKO).
72 atric skin display reduced activation of the insulin-like growth factor 1 receptor (IGF-1R) and alter
73 iates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its c
74         Here, we found in the mouse that the insulin-like growth factor 1 receptor (IGF-1R) controls
75 rs revealed 6ha as preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a pane
76            We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R) transloca
77 tor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a sub
78 ession in this lineage and was stimulated by insulin-like growth factor 1 receptor (IGF1R) activation
79 in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects as
80 s determined that LMP1 selectively activates insulin-like growth factor 1 receptor (IGF1R).
81 ang et al that describes a critical role for insulin-like growth factor 1 receptor in the progression
82 s as an autocrine activator of the beta-cell insulin-like growth factor 1 receptor signaling pathway.
83 2 (Cyclin D2), CCND1 (Cyclin D1), and IGF1R (insulin-like growth factor 1 receptor) genes involved in
84 t-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy h
85  apoptosis and liver injury by targeting the insulin-like growth factor 1 receptor.
86 gans strains with mutations in daf-2/insulin/insulin-like growth factor 1 receptor.
87 hanges in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.
88 story, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormo
89 eased expression of pro-regenerative factors insulin-like growth factor 1, leukemia inhibitory factor
90 pinal cord, and normalization of circulating insulin-like growth factor 1.
91  model assessment of insulin resistance, and insulin-like growth factor 1.
92 ation but instead sustained signaling of the insulin-like growth factor 1/phosphatidylinositol 3-kina
93                                    The human insulin-like growth factor 2 (IGF2) and insulin genes ar
94 mouse hippocampus, induces the expression of insulin-like growth factor 2 (IGF2) for the stabilizatio
95 s Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a lig
96        We addressed this question at the H19/insulin-like growth factor 2 (Igf2) imprinted locus, the
97                                              Insulin-like growth factor 2 (IGF2) is the major fetal g
98                          IMPs, also known as insulin-like growth factor 2 (IGF2) messenger RNA (mRNA)
99 t that Hh markedly induces the expression of insulin-like growth factor 2 (Igf2) that activates the m
100 activating enzyme, deiodinase-III (Dio3) and insulin-like growth factor 2 (Igf2), genes that are know
101                                              Insulin-like growth factor 2 (IGF2), produced and secret
102 he expression of several myokines, including insulin-like growth factor 2 (IGF2), whereas RNAi and do
103        Loss of SRSF3 increases expression of insulin-like growth factor 2 and the A-isoform of the in
104                        The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2
105 f the heterochronic let-7 miRNA pathway, the insulin-like growth factor 2 mRNA-binding protein 1 (IGF
106             Here, we determined that the RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF
107 ion in mutants exhibiting aberrant H19/Igf2 (insulin-like growth factor 2) imprinting.
108 iation [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis
109 or necrosis factor alpha and lower levels of insulin-like growth factor 2.
110 he growth-promoting and mitogenic effects of insulin-like growth factor 2.
111 ts known ability to promote the abundance of Insulin-like Growth Factor 2/IGF2, we find that IMP2 str
112 ing indicated substantial down-regulation of insulin-like growth factor binding protein (Igfbp) genes
113                                              Insulin-like growth factor binding protein (IGFBP)-1 inf
114 tor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor binding protein (IGFBP)-2, an
115                    Low circulating levels of insulin-like growth factor binding protein 1 (IGFBP-1) a
116                                              Insulin-like growth factor binding protein 1 (IGFBP-1) i
117                                              Insulin-like growth factor binding protein 2 (IGFBP2) is
118 that insulin-like growth factor 1 (IGF-1) or insulin-like growth factor binding protein 3 (IGFBP-3) w
119 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),
120 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a
121 -1, cartilage oligomeric matrix protein, and insulin-like growth factor binding protein 7 concentrati
122         Cartilage oligomeric matrix protein, insulin-like growth factor binding protein 7, and beta-g
123                         In this setting, the insulin-like growth factor binding protein IGFBP7 inhibi
124 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2) and 5 clin
125 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2.
126                      Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix
127 atocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, or endostat
128                                  Insulin and insulin-like growth factor I (IGF-I) signal through the
129                                Disruption of insulin-like growth factor I (IGF-I) signaling is a key
130  AD in mice responds positively to decreased insulin-like growth factor I (IGF-I) signaling, a pathwa
131 mini nutritional assessment (P = 0.003), and insulin-like growth factor I (P = 0.002), and lowered C-
132 d tumor necrosis factor receptor 1 and lower insulin-like growth factor I and leptin.
133                            Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new
134 onal immunoglobulin G1 antibody that targets insulin-like growth factor I receptor (IGF-IR).
135 ved growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL c
136 erum IL-6, tumor necrosis factor receptor 1, insulin-like growth factor I, and leptin.
137  human epidermal growth factor, insulin, and insulin-like growth factor I, particularly at the parasi
138 bolic variables, including glucose, insulin, insulin-like growth factor I, triglycerides, cholesterol
139 e gene that experiences LOI is the paracrine insulin-like growth factor IGF2, which occurs commonly i
140 ancer (insulinoma) cells that do not produce insulin-like growth factor II (IGF-II) grow slowly in pu
141                                        Since insulin-like growth factor II (IGF-II) receptors facilit
142 a systemic administration of the polypeptide insulin-like growth factor II (IGF-II) reverses all thes
143 st the effects of systemic administration of insulin-like growth factor II (IGF-II), a polypeptide th
144 antagomir-352 up-regulated the expression of insulin-like growth factor II receptor (IGF2R), which ma
145                     Inhibition of the type 1 insulin-like growth factor receptor (IGF1R) reduces the
146 the MAPK pathway, PI3Kbeta, and PI3Kalpha or insulin-like growth factor receptor 1 (IGF1R) synergisti
147  receptor (EGFR) and insulin receptor (InsR)/insulin-like growth factor receptor 1 (IGF1R), as well a
148 ative inhibition, independent of insulin and insulin-like growth factor receptor activation.
149 4 seems to exert RIBEs by acting through the insulin-like growth factor receptor DAF-2.
150 to activate PI3K signaling downstream of the insulin-like growth factor receptor.
151 oward the insulin receptor and/or the type 1 insulin-like growth factor receptor.
152                   Down-regulation of insulin/insulin-like growth factor signaling (IIS) can increase
153                                  The insulin/insulin-like growth factor signaling (IIS) pathway plays
154 e to their functional linkage to insulin and insulin-like growth factor signaling pathways.
155 o DNA damage repair, cell cycle progression, insulin-like growth factor signaling, innate immunity, a
156                                      Insulin/insulin-like growth factor signalling (IIS) is a critica
157 etabolic diseases and cancer are insulin and insulin-like growth factor signalling pathways.
158  a key role in regulating the growth hormone/insulin-like growth factor type 1 (GH/IGF1) axis, whose
159 inases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R).
160                                              Insulin-like growth factor type 2 (IGF2) receptor (IGF2R
161 eceptor isoforms A and B (IR-A and IR-B) and insulin-like growth factor type I receptor (IGF-1R).
162                         Insulin receptor and insulin-like growth factor type I receptor abundance did
163 nockdown cells was associated with increased insulin-like growth factor- 1Rbeta (IGF-1Rbeta) levels.
164  growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
165 entified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) pathway as well
166   In addition to IRBP, the IPM also contains insulin-like growth factor-1 (IGF-1) and its associated
167 scular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the
168                                              Insulin-like growth factor-1 (IGF-1) and signal transduc
169  recurrent GBM, driven by macrophage-derived insulin-like growth factor-1 (IGF-1) and tumor cell IGF-
170 e previously shown that systemic infusion of insulin-like growth factor-1 (IGF-1) exerts anti-inflamm
171 (PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals.
172                                    Exogenous Insulin-Like Growth Factor-1 (IGF-1) is neuroprotective
173 eurons, have triggered a renewed interest in insulin-like growth factor-1 (IGF-1) pathway activation
174 e MC4R, we assessed pulsatile GH release and insulin-like growth factor-1 (IGF-1) production and/or r
175                                Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF1R) si
176            In contrast, mice pretreated with insulin-like growth factor-1 (IGF-1) showed resolution o
177 atory pathway for E2F-2 production involving insulin-like growth factor-1 (IGF-1) signaling is simult
178 mediates adipogenesis and show a link to the insulin-like growth factor-1 (IGF-1) signaling pathway.
179 ells secrete a subthreshold concentration of insulin-like growth factor-1 (IGF-1) that primes the IGF
180 ce (95% CI) was computed for levels of serum insulin-like growth factor-1 (IGF-1), leptin, and adipon
181 elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IG
182 ical stimulation that significantly promoted insulin-like growth factor-1 (IGF1) production and elici
183 ion and proliferation as well as insulin and insulin-like growth factor-1 (IGF1) receptor activation
184 eration, the expression of cellular insulin, insulin-like growth factor-1 (IGF1), and GHRH receptor,
185 actors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1).
186  secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1).
187 ained only a modest amount of variability in insulin-like growth factor-1 and insulin-like growth fac
188 tress syndrome were strongly associated with insulin-like growth factor-1 and insulin-like growth fac
189                                        Total insulin-like growth factor-1 and insulin-like growth fac
190 ignificantly influence circulating levels of insulin-like growth factor-1 and insulin-like growth fac
191 , SP and its metabolites in combination with insulin-like growth factor-1 are shown to promote the co
192 Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6-9 years of age: a cros
193  Evaluation III was strongly associated with insulin-like growth factor-1 levels; and age was strongl
194  TRPC6 complementation and by treatment with insulin-like growth factor-1 or hyperforin, a TRPC6-spec
195                                          The insulin-like growth factor-1 pathway was activated to a
196                               Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine
197         In the present study, we report that insulin-like growth factor-1 receptor (Igf-1r) gene expr
198   Increased expression or signaling from the insulin-like growth factor-1 receptor (IGF-1R) has been
199  abolished these effects of insulin, whereas insulin-like growth factor-1 receptor (IGF-1R) silencing
200                The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are highly
201 -regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R).
202                         P-REX1 also promoted insulin-like growth factor-1 receptor activation, sugges
203 mmunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically
204             Treatment with recombinant human insulin-like growth factor-1 restores responses of PV(+)
205                             Impaired insulin/insulin-like growth factor-1 signalling (IGF-1) and insu
206 2 saturation and plasma glucose, insulin and insulin-like growth factor-1 were positively associated
207 ccumulation, which was confirmed in vitro as insulin-like growth factor-1, a known mediator of physio
208 ich was amplified by MCL-specific cytokines (insulin-like growth factor-1, B-cell activating factor,
209  as well as four long-lived mutants (insulin/insulin-like growth factor-1, dietary restriction, prote
210 changes including altered levels of insulin, insulin-like growth factor-1, leptin, adiponectin, stero
211 -1 and AKT following stimulation by insulin, insulin-like growth factor-1, or the neurotrophins (NGF
212             This potentiation is produced by insulin-like growth factor-1, whose binding proteins are
213 emoattractant protein-1, IL-6, IL-1beta, and insulin-like growth factor-1.
214 w this control is abrogated by inhibition of insulin-like growth factor-1R/INSR-driven phosphoinositi
215          Higher levels of apoptosis, reduced insulin-like growth factor-2 expression, and altered ant
216                                        IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is
217                                          The insulin-like growth factor-2 mRNA-binding protein 1 (IGF
218 acellular domains of the mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), domai
219 xpression of the trophoblast survival factor insulin-like growth factor-2 was significantly lower.
220 d hepatocyte nuclear factor (HNF) 4alpha and insulin-like growth factor-binding protein (IGFBP) 1 mRN
221  Binding of STC2 prevents PAPP-A cleavage of insulin-like growth factor-binding protein (IGFBP)-4 and
222 esponse elements located in the promoters of insulin-like growth factor-binding protein 1 (IGFBP1) an
223 anges in microglial secretome and identified insulin-like growth factor-binding protein 1 (IGFBP1) as
224 everal genes, e.g., Sonic hedgehog (Shh) and Insulin-like growth factor-binding protein 2 (Igfbp2), t
225                             Higher levels of insulin-like growth factor-binding protein 3 (IGFBP-3) m
226                            The regulation of insulin-like growth factor-binding protein 3 (IGFBP3) ge
227  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately
228  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients
229  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this pop
230  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in
231  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significant
232  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was no
233  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0
234 owed by a marker of cell cycle arrest (urine insulin-like growth factor-binding protein 7) and, final
235  tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7.
236 g levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 early in cr
237 854746 is also significantly associated with insulin-like growth factor-binding protein-3 levels in t
238 ciated with insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels; Acu
239       Total insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 were measur
240 iability in insulin-like growth factor-1 and insulin-like growth factor-binding protein-3.
241 levels; and age was strongly associated with insulin-like growth factor-binding protein-3.
242 746 was significantly associated with plasma insulin-like growth factor-binding protein-3.
243 cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5).
244 GFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability.
245 l and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this ef
246                     In the total population, insulin-like growth factor-I (IGF-I)-enhanced cell cycle
247 ile hormone, 20-hydroxyecdysone, and insulin/insulin-like growth factor-like signaling in regulating
248 e growth regulator downstream of the insulin/insulin-like growth factor/Tor pathways.
249 clock function and elevated transcription of Insulin-like Growth Factor2 (Igf2).
250 ance of pancreatic cancer cells by secreting insulin-like growth factors (IGF) 1 and 2, which activat
251 oming a key regulator of metabolism, whereas insulin-like growth factors (IGF)-I/II are major growth
252        We show significant overexpression of insulin-like growth factors (IGFs) in association with I
253        This review discusses the role of the insulin-like growth factors (IGFs) in controlling placen
254                                              Insulin-like growth factors (IGFs) induce proliferation
255                                  Insulin and insulin-like growth factors I and II are closely related
256                                          The insulin-like growth factors IGF1 and IGF2 are closely re
257 s of the transforming growth factor-beta and insulin-like growth factors pathways, and extracellular
258 ng roles for cancer progression, such as the insulin-like growth factors.
259 itro, resulting in higher bioavailability of insulin-like growth factors.
260              Adaptor proteins in the insulin/insulin-like-growth factor-1 signaling pathways, such as
261  of insulin-like growth factor 1 (IGF-1), an insulin-like hormone that is involved in glucose homeost
262 ulin-like peptide 8 (Dilp8) as a relaxin and insulin-like molecule secreted from growing tissues that
263 nked ins-9 gene, which encodes a new agonist insulin-like peptide (ILP) expressed specifically in the
264 ally regulating the expression of a specific insulin-like peptide (ILP), INS-6.
265 thway revealed elevated levels of Drosophila insulin-like peptide 2 (Dilp2) in the IPCs and elevated
266 no acids promote the secretion of Drosophila insulin-like peptide 2 (Dilp2), circulating sugars promo
267                                              Insulin-like peptide 3 (INSL3) is a member of the relaxi
268                                              Insulin-like peptide 5 (INSL5) has recently been discove
269            We recently identified Drosophila insulin-like peptide 8 (Dilp8) as a relaxin and insulin-
270  we showed that the expression of Drosophila insulin-like peptide 8 (dilp8), which encodes a paracrin
271 lly regulates the expression of the secreted insulin-like peptide Dilp8.
272 n identified distinct peptides that regulate insulin-like peptide expression, feeding behavior, or bo
273                                              Insulin-like peptide mediated body size plasticity in Dr
274 aling leads to insufficient expression of an insulin-like peptide, dILP8, which is required for the d
275 ong-lived dietary restricted fruit flies and insulin-like-peptide mutants exhibit small nucleoli and
276  IIS models, namely Drosophila lacking three insulin-like peptides (dilp2-3,5(-/-)) and mice lacking
277                               In Drosophila, insulin-like peptides (DILPs) are key regulators of meta
278 male-female differences in the production of insulin-like peptides (Ilps) from the IPCs do not appear
279                         In this nematode, 40 insulin-like peptides (ILPs) have been identified as put
280 s, ovary ecdysteroidogenic hormone (OEH) and insulin-like peptides (ILPs), which activate multiple pr
281  In silico target prediction identified that insulin-like peptides 7 and 8 (ilp7 and ilp8) are putati
282 pendent signals that act systemically (e.g., Insulin-like peptides [ILPs] transduced by the Target of
283  the food odor benzaldehyde (BZ) and release insulin-like peptides and acetylcholine, respectively, w
284                                 We show that insulin-like peptides are produced and secreted normally
285 in, we show that in Drosophila expression of insulin-like peptides is regulated by neprilysin activit
286  response to photoreceptor-EGF, glia produce insulin-like peptides, which induce lamina neuronal diff
287 rons producing DH44, a CRH-like peptide, and insulin-like peptides.
288 ng those that secrete some of the Drosophila insulin-like peptides.
289 y to promote somatic differentiation through Insulin-like receptor (InR) activation.
290 ecipitation of Lin-28-bound mRNAs identified Insulin-like Receptor (InR), forced expression of which
291 n mutants that enhance dauer formation in an insulin-like receptor mutant (daf-2) background.
292 ration of prostate cancer cells by promoting insulin-like responses.
293 espan extension via the suppression of IGF-1/insulin-like signaling (IIS) offers a possibility to ret
294 n as dauer by inhibiting the conserved DAF-2 insulin-like signaling (ILS) pathway through incompletel
295                                  The insulin/insulin-like signaling and target of rapamycin (IIS/TOR)
296 hese pathways to extend life span, including insulin-like signaling and the response to dietary restr
297 ynthesis, and upstream components of insulin/insulin-like signaling are activated in their discs.
298                         Furthermore, several insulin-like signaling effector genes were not significa
299 lent to normally pathogen-resistant DAF-2/16 insulin-like signaling pathway mutants.
300 lationship between components of the insulin/insulin-like/Tor and ecdysone pathways in the control of

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top